Eli Lilly Q1 2024 Adj EPS $2.58 Beats $2.46 Estimate, Sales $8.768B Miss $8.922B Estimate
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly reported Q1 2024 adjusted EPS of $2.58, surpassing the $2.46 estimate, marking a 59.26% increase from last year. However, their sales of $8.768B fell short of the $8.922B estimate, despite being a 25.98% increase from the previous year.
April 30, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eli Lilly's Q1 2024 earnings surpassed estimates with an adjusted EPS of $2.58, a significant increase from the previous year, but sales missed estimates.
The positive earnings beat suggests strong operational performance and profitability, which is typically favorable for stock sentiment. However, the miss on sales estimates could temper enthusiasm, as it may raise concerns about revenue growth sustainability. The mixed results lead to a neutral short-term impact score, as the positive earnings surprise is somewhat offset by the slight disappointment in sales.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100